Tag: AT1

Atomo Diagnostics TGA approval supply COVID-19 antibody test kit Australian market ASX AT1

Atomo Diagnostics receives TGA approval to supply COVID-19 antibody test kit to Australian market

Medical device company Atomo Diagnostics (ASX: AT1) has received approval from the Therapeutic Goods Administration for its AtomoRapid (IgG/IgM) antibody test kit for patients with suspected COVID-19....
Atomo Diagnostics ASX AT1 Access Bio COVID-19 blood based rapid testing North America

Atomo Diagnostics partners with US biotech for global marketing of COVID-19 rapid test kits

Newly-listed medical device company Atomo Diagnostics (ASX: AT1) has signed a binding agreement with US-based Access Bio Inc which will allow for the supply of Atomo’s Galileo rapid diagnostic test (R...
Atomo Diagnostics ASX AT1 COVID-19 NG Biotech blood antibody IgG:IgM AtomoRapid

Atomo Diagnostics secures exclusive rights to market COVID-19 antibody test

Medical device company Atomo Diagnostics (ASX: AT1) has penned a supplementary deal with existing business partner NG Biotech that could see over 2 million additional COVID-19 antibody tests being sol...
Atomo Diagnostics COVID-19 test device orders ASX AT1 IPO

Atomo Diagnostics secures COVID-19 test device orders ahead of ASX listing

On the eve of its ASX debut, biotech company Atomo Diagnostics (ASX: AT1) has revealed it has received additional orders for its proprietary rapid blood test devices being used to test for COVID-19. ...
Atomo Diagnostics IPO ASX medical diagnostic testing HIV RDT

Atomo Diagnostics launches $30m IPO to target global rapid diagnostic testing market

Australian medical device manufacturer Atomo Diagnostics will use a $30 million initial public offering to expand its global reach and continue development of its proprietary rapid test technologies. ...